Testing a new programming method for a stomach nerve stimulator in gastroparesis
Compares two device settings for gastroparesis symptoms in people with an Enterra stimulator.
Key facts
- Who runs it
- Enterra Medical, Inc.
- Where
- Detroit, Louisville, Portland, Seattle, St Louis, and Tampa, United StatesSee the 6 sites
- Trial code
- Registry title
- Study of Enhanced Programming Stimulation with the Enterra® Therapy System
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 25 Jul 2024
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Enterra Therapy System
- Record updated
- 15 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with idiopathic or diabetic gastroparesis (a slow-emptying stomach) who have strong nausea and vomiting. They will get an Enterra stomach stimulation device. Then they are randomly put in one of two ways of setting the device.
- Age
- 18 to 70 years at the time the Enterra device is implanted
- Sex
- Men and women
- Disease stage
- Idiopathic (no known cause) or diabetic gastroparesis. Nausea score (GCSI-DD) must average 2.5 or more per week. Vomiting must average 5 or more episodes per week.
- Earlier treatment
- People who had pyloroplasty, pyloromyotomy or G-POEM cannot join. People who did not respond to temporary gastric electrical stimulation cannot join.
- Biomarker or test result
- Slow stomach emptying on a solid meal test (Eggbeaters™ test meal) within one year: > 60% left at 2 hours and/or >10% left at 4 hours. Normal endoscopy (camera look inside the stomach) within one year.
Main reasons for not taking part
- Gastroparesis after stomach surgery, or other gut diseases that could explain the symptoms
- Pregnancy, breastfeeding, or plans to become pregnant during the study
- Active H. pylori infection, serious liver damage, serious heart disease or cancer
- Narcotics more than three days per week, drugs affecting gut movement such as GLP-1 agonists, or heavy cannabis use
- History of orthostatic intolerance, such as POTS or fainting or low blood pressure on standing
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Completed informed consent process with signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged ≥18 or ≤70 years at time of Enterra® therapy implantation
- Diagnosed with idiopathic or diabetic gastroparesis
- Delayed solid-phase gastric emptying study (Eggbeaters™ test meal), completed within one year of patient enrollment in the study. Gastroparesis defined as > 60% retained at 2 hours and/or >10% retained at 4 hours
- Investigator confirms normal endoscopy within one year of enrollment in the study
- GCSI-DD score for nausea severity during the qualifying Baseline Period averaging 2.5 or more per week and vomiting averaging 5 or more episodes per week
Who cannot take part
- Use of narcotics more than three days per week or other drugs that may affect motility (e.g., Glucagon-like peptide 1 (GLP-1) agonist drug)
- Previous diagnosis or history of orthostatic intolerance, e.g., POTS, neurocardiogenic syncope, orthostatic hypotension
- Post-surgical gastroparesis (e.g., fundoplication, Billroth I or II) or other active stomach or gastrointestinal diseases disorders which could explain symptoms in the opinion of the investigator
- History of pyloroplasty or pyloromyotomy or G-POEM
- Active H. pylori infection
- Metabolic, mechanical, or mucosal inflammatory causes that may explain GI symptoms such as gallbladder disease, small bowel bacterial overgrowth, IBS, inflammatory bowel disease, celiac disease, liver or pancreatic disease, or bowel obstruction
- Patients with significant cardiac or cardiovascular disease, malignancy, or other conditions
- Subjects with an underlying disease leading to follow-up by MRI outside of current MR conditional indications
- Significant hepatic injury (elevated ALT, AST, bilirubin)
- Pregnancy or breastfeeding at the time of consent, or intent to become pregnant during the study
- Participation in other clinical studies
- Cannabis and/or cannabinoid use that exceeds either:; Greater than 3 days of usage per week with 2 or less occurrences each day of use, or; Greater than 3 grams of total usage per week
- Subject experiences discomfort during stimulation assessment that cannot be tolerated
- Evidence of a failed response to temporary gastric electrical stimulation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Henry Ford Health SystemDetroit, United StatesContact: Daniel MolitorTaking people
- University of LouisvilleLouisville, United StatesContact: Amy PerdueTaking people
- Foundation for Surgical InnovationPortland, United StatesContact: Angi GillTaking people
- Benaroya Research Institute at Virginia MasonSeattle, United StatesContact: Cheryl ShawTaking people
- Washington UniversitySt Louis, United StatesContact: Asima BadicTaking people
- University of South FloridaTampa, United StatesContact: Beth MonteraTaking people
About the trial
What the trial wants to find out
The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life measures.
Read full original descriptionShow less
Participants in this study will be evaluated for study entry criteria, have an Enterra Therapy System implanted, and be randomly assigned to one of two programming strategies. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at monthly study visits.
Participants will be involved in the study for up to six months after treatment assignment.
Programming parameters in the study are within currently approved labeling.
The 2 groups in the trial
- Control Programming StimulationExisting treatment, for comparison
Begin with nominal (lower stimulation) programming settings at Enterra Therapy System implantation. At treatment assignment, nominal programming will continue. Slight increases in device amplitude (stimulation) will be done at 3 Month visit and at later follow-up visits.
Treatment: Enterra Therapy System
- Enhanced Programming StimulationTreatment being tested
Begin with nominal (lower stimulation) programming settings at Enterra Therapy System implantation. At treatment assignment, moderate increases in device amplitude (stimulation) and duty cycle (on/off cycles) will be done. Further adjustments to amplitude, duty cycle, and/or frequency (rate of pulses) will be done at follow-up visits.
Treatment: Enterra Therapy System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Examination of Programming with the Enterra® Therapy System in a Double-Blinded, Randomized, Prospective Study in the Treatment of Nausea and Vomiting Symptoms Using Gastric Electrical Stimulation
- Plain-language title
- Testing a new programming method for a stomach nerve stimulator in gastroparesisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06560307, who can take part
- Record updated
- 15 November 2024